Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 16 | 2023 | 325 | 2.550 |
Why?
|
| Hydroxyurea | 9 | 2016 | 86 | 1.550 |
Why?
|
| Antisickling Agents | 5 | 2013 | 19 | 0.970 |
Why?
|
| Iron | 5 | 2009 | 300 | 0.720 |
Why?
|
| Fetal Hemoglobin | 4 | 2016 | 26 | 0.690 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 2754 | 0.610 |
Why?
|
| Stroke | 3 | 2023 | 1030 | 0.530 |
Why?
|
| Phosphoglycerate Kinase | 2 | 2006 | 6 | 0.500 |
Why?
|
| Anemia, Hemolytic | 2 | 2006 | 30 | 0.490 |
Why?
|
| Exome | 3 | 2017 | 1064 | 0.480 |
Why?
|
| Mutation, Missense | 3 | 2020 | 890 | 0.470 |
Why?
|
| Genetic Variation | 5 | 2024 | 1509 | 0.420 |
Why?
|
| DNA Damage | 5 | 2024 | 498 | 0.410 |
Why?
|
| Pyrophosphatases | 1 | 2013 | 22 | 0.390 |
Why?
|
| Erythrocytes | 2 | 2021 | 190 | 0.390 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 67 | 0.390 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2007 | 38 | 0.390 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1569 | 0.380 |
Why?
|
| Iron Overload | 2 | 2009 | 16 | 0.370 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2024 | 54 | 0.370 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2010 | 6 | 0.330 |
Why?
|
| Inflammasomes | 2 | 2022 | 149 | 0.320 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 1206 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 1709 | 0.310 |
Why?
|
| Genetic Markers | 1 | 2011 | 599 | 0.300 |
Why?
|
| beta-Thalassemia | 1 | 2009 | 26 | 0.300 |
Why?
|
| Haplotypes | 3 | 2013 | 525 | 0.300 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 1206 | 0.300 |
Why?
|
| Caspase 2 | 2 | 2024 | 27 | 0.290 |
Why?
|
| Intestinal Absorption | 2 | 2007 | 170 | 0.290 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 136 | 0.280 |
Why?
|
| Mutation | 5 | 2024 | 5950 | 0.270 |
Why?
|
| Hemochromatosis | 1 | 2007 | 38 | 0.250 |
Why?
|
| Genomics | 1 | 2014 | 1549 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3271 | 0.250 |
Why?
|
| Amidohydrolases | 1 | 2006 | 22 | 0.250 |
Why?
|
| Pyridoxal Kinase | 1 | 2006 | 2 | 0.250 |
Why?
|
| Liver | 3 | 2009 | 1765 | 0.250 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 109 | 0.240 |
Why?
|
| Receptors, Transferrin | 1 | 2006 | 12 | 0.240 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 2314 | 0.240 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2006 | 78 | 0.240 |
Why?
|
| Child, Preschool | 13 | 2024 | 14463 | 0.230 |
Why?
|
| Child | 16 | 2024 | 25298 | 0.220 |
Why?
|
| Hemolysis | 3 | 2022 | 103 | 0.220 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 1732 | 0.220 |
Why?
|
| UDPglucose-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 2 | 0.210 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 338 | 0.210 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 336 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2006 | 415 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 199 | 0.200 |
Why?
|
| Adolescent | 13 | 2024 | 20156 | 0.200 |
Why?
|
| Apoptosis | 2 | 2024 | 1823 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 486 | 0.180 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 394 | 0.180 |
Why?
|
| Humans | 32 | 2024 | 127514 | 0.180 |
Why?
|
| Caspases, Initiator | 1 | 2021 | 5 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2020 | 4988 | 0.170 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2021 | 29 | 0.170 |
Why?
|
| Inflammation | 3 | 2022 | 1435 | 0.170 |
Why?
|
| Carrier Proteins | 3 | 2016 | 1011 | 0.170 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2020 | 13 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2023 | 256 | 0.160 |
Why?
|
| Caspases | 1 | 2021 | 156 | 0.160 |
Why?
|
| Blood Group Antigens | 1 | 2020 | 57 | 0.160 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 19 | 0.150 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 11 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2024 | 2400 | 0.150 |
Why?
|
| Blood Cells | 1 | 2019 | 55 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2020 | 246 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 222 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2022 | 506 | 0.150 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 137 | 0.150 |
Why?
|
| Hepcidins | 3 | 2007 | 27 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 549 | 0.140 |
Why?
|
| Chronic Disease | 3 | 2009 | 1199 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 270 | 0.140 |
Why?
|
| Gene Frequency | 3 | 2020 | 740 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 327 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1008 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 174 | 0.130 |
Why?
|
| Macrophages | 1 | 2021 | 643 | 0.130 |
Why?
|
| Genotype | 4 | 2024 | 2600 | 0.130 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 99 | 0.120 |
Why?
|
| Albuminuria | 1 | 2016 | 104 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 788 | 0.120 |
Why?
|
| Male | 15 | 2024 | 62896 | 0.120 |
Why?
|
| Transcriptome | 1 | 2022 | 1072 | 0.120 |
Why?
|
| beta-Globins | 2 | 2013 | 9 | 0.110 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 2013 | 16 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 503 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2016 | 764 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 201 | 0.110 |
Why?
|
| Female | 14 | 2024 | 68771 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1601 | 0.100 |
Why?
|
| Risk Factors | 4 | 2016 | 10636 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1485 | 0.090 |
Why?
|
| Heme | 2 | 2022 | 52 | 0.090 |
Why?
|
| RNA | 2 | 2022 | 518 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2011 | 9 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2022 | 150 | 0.090 |
Why?
|
| Mice | 6 | 2024 | 17695 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2016 | 2345 | 0.080 |
Why?
|
| Micronucleus Tests | 1 | 2010 | 3 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 197 | 0.080 |
Why?
|
| Infant | 5 | 2024 | 12810 | 0.080 |
Why?
|
| Time | 1 | 2010 | 94 | 0.080 |
Why?
|
| Brazil | 2 | 2023 | 138 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 1892 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 784 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2012 | 4489 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2009 | 251 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 4309 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 572 | 0.070 |
Why?
|
| Adult | 7 | 2023 | 30609 | 0.070 |
Why?
|
| Alleles | 3 | 2020 | 1610 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2016 | 6250 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2009 | 256 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 686 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 14 | 0.070 |
Why?
|
| Mice, Inbred AKR | 1 | 2007 | 16 | 0.070 |
Why?
|
| Hemochromatosis Protein | 1 | 2007 | 21 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 99 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 4513 | 0.060 |
Why?
|
| Animals | 6 | 2024 | 33213 | 0.060 |
Why?
|
| Luciferases | 1 | 2007 | 125 | 0.060 |
Why?
|
| Endotoxins | 1 | 2007 | 50 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 144 | 0.060 |
Why?
|
| Spain | 1 | 2006 | 60 | 0.060 |
Why?
|
| Solubility | 1 | 2006 | 123 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 314 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2006 | 63 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 97 | 0.060 |
Why?
|
| Protein Folding | 1 | 2006 | 214 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 359 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1774 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 289 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1487 | 0.060 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 5 | 0.060 |
Why?
|
| Galactosemias | 1 | 2004 | 14 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2901 | 0.050 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 48 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 720 | 0.050 |
Why?
|
| Alu Elements | 1 | 2004 | 67 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 742 | 0.050 |
Why?
|
| ADAMTS Proteins | 1 | 2023 | 10 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 333 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2023 | 78 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2009 | 3720 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 24 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 2760 | 0.050 |
Why?
|
| Alarmins | 1 | 2021 | 5 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 125 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 717 | 0.040 |
Why?
|
| DNA | 1 | 2006 | 1422 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 237 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2542 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 132 | 0.040 |
Why?
|
| Syndrome | 2 | 2017 | 1137 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 417 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 584 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12582 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2006 | 1045 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 827 | 0.040 |
Why?
|
| Exons | 1 | 2020 | 757 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1871 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3503 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Duffy Blood-Group System | 1 | 2016 | 8 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 2016 | 70 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 96 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 799 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 247 | 0.030 |
Why?
|
| Young Adult | 2 | 2023 | 9705 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 204 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 757 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 422 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 355 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1638 | 0.030 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 4 | 0.030 |
Why?
|
| alpha-Thalassemia | 1 | 2013 | 12 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2013 | 48 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 539 | 0.030 |
Why?
|
| Middle Aged | 3 | 2023 | 27894 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 539 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 64 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8371 | 0.020 |
Why?
|
| Bilirubin | 1 | 2013 | 124 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 900 | 0.020 |
Why?
|
| V(D)J Recombination | 1 | 2011 | 5 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 13 | 0.020 |
Why?
|
| CRADD Signaling Adaptor Protein | 1 | 2009 | 4 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 11 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2009 | 21 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2009 | 39 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 735 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 155 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 299 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 138 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 70 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 138 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 578 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 361 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 684 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 549 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1602 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 494 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 948 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1092 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 680 | 0.020 |
Why?
|
| Ireland | 1 | 2004 | 29 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 729 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 914 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 399 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17081 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5160 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3714 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 4804 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 2312 | 0.010 |
Why?
|
| Diet | 1 | 2007 | 1105 | 0.010 |
Why?
|